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Summary In the Maheba Refugee Settlement, in the clinics supported by Me ´decins Sans Frontie `res, all children
aged up to 5 years with a conﬁrmed diagnosis of uncomplicated falciparum malaria are treated with the
combination of sulfadoxine/pyrimethamine (SP) and artesunate (AS). We compared the treatment’s
efﬁcacy and effectiveness. Patients were randomized in order to receive the treatment supervised
(efﬁcacy) or unsupervised (effectiveness). Therapeutic response was determined after 28 days of follow
up. The difference between recrudescence and re-infection was ascertained by polymerase chain reaction
(PCR). We also assessed genetic markers associated to SP resistance (dhfr and dhps). Eighty-ﬁve patients
received treatment under supervision and 84 received it unsupervised. On day 28, and after PCR
adjustment, efﬁcacy was found to be 83.5% (95% CI: 74.1–90.5), and effectiveness 63.4% (95% CI:
52.6–73.3) (P < 0.01). Point mutations on dhfr (108) and dhps (437) were found for 92.0% and 44.2%
respectively of the PCR samples analysed. The signiﬁcant difference in therapeutic response after
supervised and unsupervised treatment intake can only be explained by insufﬁcient patient adherence.
When implementing new malaria treatment policies, serious investment in ensuring patient adherence is
essential to ascertain the effectiveness of the new treatment schedules.
keywords malaria, Plasmodium falciparum, efﬁcacy, effectiveness, artemisinin-based combination
therapy, refugee settlement, Zambia
Introduction
The high burden of malaria on the African continent,
aggravated by the increasing spread of parasites resistant to
the currently used antimalarial drugs, is well-documented
(White et al. 1999; Bloland 2001; Trape 2001). One
strategy to improve cure rates and limit the development of
drug resistance is the use of artemisinin-based combination
therapy (ACT) (White & Olliaro 1996; White 1999;
Guerin et al. 2002). A meta-analysis including almost 6000
patients showed higher cure rates, faster parasite clearance
and a decreased gametocyte carriage with ACT than
monotherapy (International Artemisinin Study Group
2004). The introduction of ACT implies that the long
treatment course of chloroquine or the convenient single
dose of sulfadoxine-pyrimethamine (SP) are replaced by
new 3-day course therapies. However, poor patient
adherence to such novel protocols would impair treatment
effectiveness, and favour the development of resistance
(Nosten & Brasseur 2002). In Zambia, resistance has been
measured at 54% for chloroquine, and between 16 and
26% for SP (Bijl et al. 2000; National Malaria Control
Centre 2000). In November 2001, in the Maheba Refugee
Settlement (North-Western Province), Me ´decins Sans
Frontie `res (MSF) introduced the combination of SP single
dose and 3 days artesunate (AS), for the treatment of
uncomplicated falciparum malaria, conﬁrmed by a rapid
diagnostic test (Paracheck Pf , Orchid Biomedical System,
Goa, India), in children of 5 years or younger. After
3 months of using this new protocol, assessment of patient
adherence revealed that 21% of the patients had leftover
tablets on the day after the last treatment dose, and that
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incorrect timing and/or dosage (Depoortere et al. 2004). In
order to assess the impact of this limited adherence, we
compared the treatment efﬁcacy and effectiveness, i.e. the
therapeutic response after supervised and unsupervised
drug intake, respectively.
Materials and methods
Study area and population
Patients were recruited in clinic H of the Maheba Refugee
Settlement, the characteristics of which are described
elsewhere (Depoortere et al. 2004). Eligible for study
participation were children between 6 and 59 months of
age, weighing at least 5 kg, with fever (axillary tempera-
ture ‡37.5  C) or history of fever in the past 24 h and with
a microscopically conﬁrmed monoinfection of Plasmodium
falciparum (parasitaemia ‡2000/ll and <100 000/ll).
Children with danger signs or signs of severe malaria
according to the World Health Organisation (WHO)
criteria, with a history of allergy to SP or living at more
than 1.5 h walking distance from the health clinic were
excluded from study participation (WHO 1996, 2002).
Enrolment procedure
Patients suspected with malaria during the outpatient
consultation were sent to the malaria study clinic. After
clinical examination, a thick and thin smear was taken and
haemoglobin measured. For patients fulﬁlling all inclusion/
exclusion criteria, written informed consent was obtained.
Randomized in blocks of 10, children were assigned to be
given treatment either in a supervised or unsupervised way.
Before receiving any treatment, a blood sample was taken
on ﬁlter paper for nested polymerase chain reaction (PCR)
analysis.
Treatment
The treatment schedule to be evaluated consisted of a
single dose SP (sulfadoxine 500 mg and pyrimethamine
25 mg, International Dispensary Association, the Nether-
lands; based on 25 mg sulfadoxine/kg) and 3 days AS
(artesunate 50 mg, Dafra Pharma nv, Belgium; 1 dose/day,
4 mg/kg/day). Children in the supervised arm were given
the ﬁrst dose at the health clinic, and were asked to return
on the following 2 days for observed intake of the whole
treatment. The supervised doses were given with great care,
ensuring that no medication was spilled, spit or vomited;
for the smallest children, tablets were crushed and given by
means of a spoon or a syringe. In case vomiting occurred, a
second attempt to give the treatment was made after
30–60 min. When the child vomited any of the supervised
doses more than once, intravenous rescue treatment was
given [artemether (3.2 mg/kg/day the ﬁrst day, and 1.6 mg/
kg/day the second and the third days), or quinine hydro-
chloride (10 mg/kg/8 h for 7 days)]. Children in the
unsupervised arm were prescribed the SP/AS combination
on their health cards, to receive the complete treatment at
the pharmacy, with explanation for home administration,
as was done under usual circumstances. No further
measures were undertaken for the treatment of these
patients.
Patient follow up
Follow up was done according to WHO guidelines (WHO
1996, 2002). Visits for both groups were scheduled on day
3, 7, 14, 21 and 28, during which a clinical and
parasitological examination was conducted. In case of
parasitaemia after day 9, a second PCR sample was taken.
The presence of gametocytes was assessed on day 14 and
28, and haemoglobin levels were measured on day 28. If
perceived necessary, patients were free to attend the
malaria study clinic at any time during follow up. Children
were withdrawn from the study in case of failure to take
any of the supervised doses, vomiting any of the supervised
dose more than once, danger signs or severe disease, self-
medication with any antimalarial, decision of the parent or
guardian, or mistaken inclusion. Patients for whom the
outcome could not be determined were considered lost to
follow up.
Classiﬁcation of therapeutic outcomes
Following WHO criteria for intense transmission areas,
early treatment failure (ETF) was deﬁned as (i) signs of
severe malaria with parasitaemia on day 1, 2 or 3; or (ii)
parasitaemia on day 2 exceeding parasitaemia of day 0
combined with fever; or (iii) parasitaemia on day 3
exceeding 25% of parasitaemia of day 0; or (iv) fever and
parasitaemia on day 3 (WHO 2002). Late clinical failure
(LCF) was deﬁned as any parasitaemia between day 4 and
day 28 in the presence of fever. Patients were classiﬁed as
late parasitological failure (LPF) when they presented
positive parasitaemia on day 28, but without any clinical
signs. Finally, patients showing negative parasitaemia on
day 28 were classiﬁed as adequate clinical and parasito-
logical response (ACPR). Children classiﬁed as ETF or
LCF during the follow-up period, as well as children
classiﬁed as LPF on day 28, received oral quinine
hydrochloride as rescue treatment (10 mg/kg/8 h for
7 days).
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A thin and thick smear were prepared on the same slide
and stained using 10% Giemsa solution. Each blood slide
was read blindly by two technicians. In case of disagree-
ment, the reading of a third technician would decide on the
ﬁnal result. We also had external quality control. Parasit-
aemia was quantiﬁed by counting asexual parasites against
200 white blood cells (WBCs) and assuming a normal
WBC level of 8000/ll. Presence of gametocytes was
ascertained counting 200 WBCs, or 500 WBCs in case no
trophozoites were seen. Haemoglobin levels were meas-
ured by means of a Lovibond . Samples for PCR geno-
typing were collected on Isocode
TM Stix (Schleicher &
Schuell, Dassel, Germany), on day 0 for every patient
included, and a second for every child presenting with
positive parasitaemia after day 9. In vitro resistance to SP
was assessed through the prevalence on day 0 of point
mutations on codon 108 on the dhfr gene, and on codon
437 on the dhps gene (Kublin et al. 2002). Recrudescence
was distinguished from re-infection by comparison of msa-
2 gene polymorphism (Contamin et al. 1995). DNA
extraction, seminested PCR followed by restriction frag-
ment length polymorphism (RFLP) methods using speciﬁc
enzymes were performed at the Laboratoire de Parasitol-
ogie Me ´dicale, Faculte ´ de Me ´decine, in Rouen (France)
according to published protocols (Vasconcelos et al. 2000).
Sample size
Considering the data on SP resistance in Zambia on one
hand, and comparisons of AS efﬁcacy in monotherapy vs.
the combination of AS/SP on the other, efﬁcacy was
estimated at 90% (Von Seidlein et al. 2000). Taking into
account the results of the adherence study on the same site
a little earlier, effectiveness was estimated at 70%
(Depoortere et al. 2004). To detect this 20% difference,
with a type 1 error of 0.05 and a power of 80%, 70
children were required in each treatment arm. Planning for
a 20% loss to follow up, the total sample size was
estimated at 168 children.
Statistical analysis
Data were daily entered using Microsoft Excel  (Ofﬁce
2000), and analysed using epi-info 6.04 software (CDC,
Atlanta, USA) and SPSS  version 10.0.5 (SPSS Inc.,
Chicago, IL, USA). All data were individually checked for
incoherencies. Treatment outcomes are expressed as
proportions of the total analysable results. Mean values for
temperature and haemoglobin concentration were
compared using t-distribution and anova test statistic.
Comparisons between proportions were done using the
chi-square test and presented with a 95% conﬁdence
interval and P-value.
Ethics
The study protocol was approved by the Zambian
Research Ethics Committee.
Results
Study proﬁle and baseline characteristics
The study was conducted between March and June 2002.
Of 333 patients screened, 169 were included: 85 (50.3%)
were randomized in the supervised arm, and 84 (49.7%) in
the unsupervised arm (Figure 1). None of the patients
reported intake of antimalarial treatment before the
consultation. There was no difference in baseline charac-
teristics between the two treatment arms (Table 1). Eight
patients (4.7%) were withdrawn from the study, six
(7.0%) in the supervised group (three for vomiting and
three for self-medication) and two (2.4%) in the
unsupervised group (one for vomiting and one for self-
medication) (P ¼ 0.28). None of the patients was lost to
follow up.
Therapeutic response
On day 14, treatment efﬁcacy was estimated at 86.6%
(95% CI: 77.9–92.7) and treatment effectiveness at 71.9%
(95% CI: 61.5–80.9) (P ¼ 0.02). On day 28, and after
PCR adjustment, treatment efﬁcacy was 83.5% (95% CI:
74.1–90.5) and its effectiveness 63.4% (95% CI: 52.6–
73.3) (P ¼ 0.004) (Table 2). There was no difference
between the supervised and unsupervised group in the
proportion of patients with fever on day 0 (50.6% vs.
57.8% respectively; P ¼ 0.35) or day 3 (4.8% vs. 2.5%;
P ¼ 0.70). There was no signiﬁcant difference either in the
proportion of patients with gametocytes on day 0 (11.8%
vs. 19.0%; P ¼ 0.19) or during follow up on day 14 (4.8%
vs. 4.9%; P ¼ 0.74) and day 28 (5.9% vs. 8.3%;
P ¼ 0.84). Lastly, for the 62 children in the supervised
group anaemic on day 0 (deﬁned as haemoglobin <11 g/dl),
the anaemia had disappeared on day 28 for 30 of them
(48.4%). In the unsupervised group, anaemia disappeared
for 25 of 56 children (44.6%) (P ¼ 0.68).
Genomic analysis
All 113 PCR samples from day 0 were analysed for
mutations related to SP resistance. Point mutations on
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of the samples on inclusion (90.4% in the supervised
group, 93.4% in the unsupervised group, P ¼ 0.80). On
codon dhps (437), point mutations were present in 44.2%
(95% CI: 34.9–53.9) of the samples, 36.5% in the
supervised, and 50.8% in the unsupervised group
(P ¼ 0.12) (Table 3). In patients that were ﬁnally classiﬁed
as treatment failures, there was no statistically signiﬁcant
333 Patients screened
169 Patients included
85 In the supervised group 84 In the unsupervised group
3 Withdrawn 1 Withdrawn
2 Day 0: vomiting Day 0: vomiting
1 Day 1: vomiting 1 ETF
82 To be analysed day 14 82* To be analysed day 14
3 Withdrawn 1 Withdrawn
Day 20, 22, 26: Day 15:
auto-medication auto-medication
79 Final classification day 28† 81 Final classification day 28†
20 LPF 23 LCF 36 ACPR 29 LPF 32 LCF 20 ACPR
1 Day 17 5 Day 14
1 Day 19 1 Day 17
12 Day 21 1 Day 20
1 Day 23 12 Day 21
8 Day 28 1 Day 25
2 Day 26
10 Day 28
Figure 1 Study proﬁle. Clinic H, Maheba, Zambia (March–June 2002).
* One patient did not show up on day 14 and could therefore not be included in the day 14 analysis.  Results before polymerase chain
reaction (PCR) adjustment.
Table 1 Socio-demographic and clinical
characteristics of patients on inclusion
(clinic H, Maheba, Zambia, March–June
2002)
Supervised (n ¼ 85) Unsupervised (n ¼ 84) P-value
Mean age (months) (SD) 23.6 (12.5) 21.4 (13.4) 0.27
Mean weight (kg) (SD) 9.5 (2.0) 9.5 (2.4) 0.93
Gender ratio (M/F) 0.81 (38/47) 0.91 (40/44) 0.76
Mean temperature ( C) (SD) 37.6 (1.1) 37.8 (1.2) 0.26
Median haemoglobin
(g/dl) (range)
9.2 (5.3–12.2) 9.4 (5.3–12.7) 0.46
Geometric mean
parasitaemia (range)
16 022 (2224–90 435) 19 185 (2185–97 953) 0.41
Gametocytes 10 (11.8%) 16 (19.0%) 0.19
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of point mutations. For dhfr (108), in the supervised arm
there were 27.7% of the patients with a point mutation
and 41.8% in the unsupervised arm (P ¼ 0.14). For dhps
(437), these proportions were 10.6% and 25.4% respect-
ively (P ¼ 0.05). When considering the mixed proﬁles as
resistant as well (mutations are selected after SP treatment),
proportions became 97.3% (95% CI: 92.4–99.4) and
59.3% (95% CI: 49.6–68.4), respectively.
Discussion
We compared the efﬁcacy and effectiveness of the combi-
nation of SP and AS in children under 5 years of age. After
14 and 28 days of follow up, we found that, in Maheba,
cure rates obtained with the combination AS/SP were
signiﬁcantly lower when drugs were given under normal
ﬁeld conditions. The difference between the two groups
might have been slightly overestimated: while in the
efﬁcacy group each dose intake was supervised and
vomiting systematically led to exclusion, in the unsuper-
vised group exclusion happened only if vomiting occurred
during the inclusion process. However, since only three
children had to be excluded in the supervised group, and
since randomization did not show any difference between
the two groups on inclusion, we strongly believe this had
limited inﬂuence on our results. No difference between the
two treatment groups was found for the clearance of fever
and parasites on day 3, disappearance of gametocytes on
day 14 and 28, or improvement of haemoglobin levels on
day 28. We have no knowledge of previous studies that
investigated the effectiveness of ACT after a 28-day follow
up and with PCR adjustment, in routine conditions, to
compare with our results.
The reduced efﬁcacy of AS/SP we found (83.5% after
28 days) is most likely due to the high resistance levels to
SP. In 1998 and 1999, in vivo studies estimated SP
resistance in two different regions of the country at 26 and
16% (Bijl et al. 2000; National Malaria Control Centre
2000). The high proportion of genetic mutations in
Maheba, linked to pyrimethamine and sulfadoxine resist-
ance, suggests that resistance levels might be even higher
than these estimates. However, because only one point
mutation was considered on both genes (possibly leading to
an overestimation of resistance levels), true resistance
probably lies somewhere between the in vivo and genetic
results (Peterson et al. 1988; Omar et al. 2001; Kublin
et al. 2002). In any case, these results suggest that the use
of SP, even combined to an artemisinine derivative, is no
Table 2 Therapeutic response at day 14
and day 28 of both supervised and
unsupervised treatment groups, corrected
by PCR (clinic H, Maheba, Zambia,
March–June 2002)
Supervised Unsupervised
n % 95% CI n % 95% CI
Outcome at day 14
Early treatment failure 0 0.0 0.0–3.6 1 1.2 0.1–5.9
Late clinical failure 0 0.0 0.0–3.6 5 6.1 2.3–13.0
Late parasitological failure 11* 13.4 7.3–22.1 17 20.7 13.0–30.5
Adequate clinical and
parasitological response
71 86.6 77.9–92.7 59 71.9 61.5–80.9
Total 82 100.0 82 100.0
Outcome at day 28
Early treatment failure 0 0.0 0.0–3.6 1 1.2 0.1–5.9
Late clinical failure 6 7.6 3.1–15.1 13 15.9 9.1–25.0
Late parasitological failure 7 8.9 3.9–16.7 16 19.5 12.0–29.1
Adequate clinical and
parasitological response
66 83.5 74.1–90.5 52 63.4 52.6–73.3
Total 79 100.0 82 100.0
PCR, polymerase chain reaction; CI, conﬁdence interval.
* One patient came on day 15 for follow up, instead of on day 14.
Table 3 Prevalence of point mutations on the dhfr and dhps genes
(day 0 samples; clinic H, Maheba, Zambia, March–June 2002)
n % 95% CI
dhfr (108)
Resistant 104 92.0 85.4–96.3
Mixed 6 5.3 2.0–11.2
Sensitive 3 2.7 0.5–7.6
Total 113 100.0
dhps (437)
Resistant 50 44.3 34.9–53.9
Mixed 17 15.0 9.0–23.0
Sensitive 46 40.7 31.6–50.3
Total 113 100.0
Tropical Medicine and International Health volume 10 no 2 pp 139–145 february 2005
E. Depoortere et al. Efﬁcacy and effectiveness of ACT, Zambia
ª 2005 Blackwell Publishing Ltd 143longer indicated in Maheba. At the time of our study, the
Zambian government was considering to change national
policy, which prescribed chloroquine as ﬁrst-line
treatment. Country policy now prescribes artemether-
lumefantrine.
The observed drop in cure rates after unsupervised drug
intake, from 83.5 to 63.4%, is likely to be mainly, if not
completely, because of poor patient adherence. The previ-
ously completed adherence study indicates the same
assumption. Our results underline the signiﬁcant implica-
tions of non-adherence, particularly in case of moderate
efﬁcacy. When preparing changes in malaria treatment
policy, decisions are usually based on treatment efﬁcacy
measures only. However, more attention should be paid to
the testing of new treatment protocols in true ﬁeld
conditions. We strongly believe that ACT is the only
alternative for effective treatment of P. falciparum malaria
today. However, serious investment is needed to monitor
and improve patient adherence to treatment, in order to
ensure that the drugs truly cure the patients.
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